StockData
Lexaria Bioscience Corp. logo

Lexaria Bioscience Corp. (LEXX) stock

LEXXNasdaqPharmaceutical PreparationsFiscal year ends August 31
Financials through Q3 FY2026, quarter ended May 31, 2026Last filing: 10-Q on Jul 13, 2026Score 8/30
$4.28+0.10 (+2.39%)

Close on Nov 18, 2026Market cap $106.09MP/E –Yield –

Lexaria Bioscience operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Lexaria Bioscience's operating income for the twelve months ending May 31, 2026 was -$7.71M. For fiscal 2025 it was -$11.88M. The highest annual figure on record is -$1.28M in fiscal 2016.

Annual operating income

PeriodPeriod endValueChange
FY2025Aug 31, 2025-$11.88M–
FY2024Aug 31, 2024-$5.75M–
FY2023Aug 31, 2023-$6.53M–
FY2022Aug 31, 2022-$6.62M–
FY2021Aug 31, 2021-$5.69M–
FY2016Aug 31, 2016-$1.28M–
FY2015Aug 31, 2015-$1.98M–

Quarterly operating income

Change is against the same quarter a year earlier.

Periods
PeriodPeriod endValueChange
Q3 FY2026CQ2 2026May 31, 2026-$1.99M–
Q2 FY2026CQ1 2026Feb 28, 2026-$1.45M–
Q1 FY2026CQ4 2025Nov 30, 2025-$1.57M–
Q4 FY2025CQ3 2025Aug 31, 2025-$2.69M–
Q3 FY2025CQ2 2025May 31, 2025-$3.75M–
Q2 FY2025CQ1 2025Feb 28, 2025-$2.75M–
Q1 FY2025CQ4 2024Nov 30, 2024-$2.69M–
Q4 FY2024CQ3 2024Aug 31, 2024-$2.20M–
Q3 FY2024CQ2 2024May 31, 2024-$1.74M–
Q2 FY2024CQ1 2024Feb 29, 2024-$668.01K–
Q1 FY2024CQ4 2023Nov 30, 2023-$1.14M–
Q4 FY2023CQ3 2023Aug 31, 2023-$1.11M–
Q3 FY2023CQ2 2023May 31, 2023-$2.40M–
Q2 FY2023CQ1 2023Feb 28, 2023-$1.32M–
Q1 FY2023CQ4 2022Nov 30, 2022-$1.70M–
Q4 FY2022CQ3 2022Aug 31, 2022-$748.55K–
Q3 FY2022CQ2 2022May 31, 2022-$2.42M–
Q4 FY2021CQ3 2021Aug 31, 2021-$1.30M–
Q3 FY2021CQ2 2021May 31, 2021-$2.57M–
Q2 FY2018CQ1 2018Feb 28, 2018-$1.38M–
Q1 FY2018CQ4 2017Nov 30, 2017-$578.71K–
Q2 FY2017CQ1 2017Feb 28, 2017-$464.98K–
Q1 FY2017CQ4 2016Nov 30, 2016-$400.55K–
Q4 FY2016CQ3 2016Aug 31, 2016-$326.75K–

More Lexaria Bioscience figures

See a number that looks wrong?